

**Amendments to the claims:**

This listing of claims replaces all prior versions, and listings, of claims in the application.

**Listing of claims:**

Claims 1-24 (canceled).

25 (currently amended): ~~An isolated peptide having an amino acid sequence selected from the group~~

A compound consisting of

X01-Thr Gly Ser Phe Phe Ser Glu Leu Trp Thr Ser (SEQ ID NO: 1) -X12 ~~and or~~

X01-Glu Tyr Gly Ser Phe Phe Ser Glu Leu Trp Thr Ser (SEQ ID NO: 2) -X12,

wherein

X01 = acetyl group, biotin group, fluorescent label, spacer, linker, or deletion;

X12 = amide, the free acid, GK<sup>3</sup>KR<sup>3</sup>, or a spacer,

wherein R<sup>3</sup> is an acid amide or a free acid or a spacer[,]

~~with the proviso that a maximum of one non-conservative amino acid exchange is effected per amino acid position in the sequence, wherein "non-conservative exchange" means is an exchange of amino acids between the groups mentioned below:~~

~~Group I: Leu, Ile, Val, Met, His, Trp, Tyr, Phe,~~

~~Group II: Glu, Gln, Asp, Asn;~~

~~Group III: Ser, Thr, Cys, Gly, Ala, Pro;~~

~~Group IV: Lys, Arg.~~

26 (currently amended): The ~~peptide~~ compound according to claim 25, characterized by being:

TGSFF SELWT SGKK-amide or free acid,

E YGSFF SELWT SGKK-amide or free acid, which may also be acetylated N-terminally.

27 (currently amended): The ~~peptide~~ compound according to claim 25, characterized by being

bound by antibodies of patients suffering from dilatative cardiomyopathy.

28 (currently amended): The ~~peptide~~ compound according to claim 25, characterized in that said

linker is selected from the group consisting of:

- $\alpha$ -aminocarboxylic acids or their homo- and heterooligomers;
- $\alpha$ ,  $\omega$ -aminocarboxylic acids or their branched homo- or heterooligomers;
- other amino acids or their linear or branched homo- or heterooligomers (peptides);
- amino-oligoalkoxy-alkylamines;
- maleirimiidocarboxylic acid derivatives;
- oligomers of alkylamines;
- 4-alkylphenyl derivatives;

- 4-oligoalkoxyphenyl or 4-oligoalkoxyphenoxy derivatives;
- 4-oligoalkylmercaptophenyl or 4-oligoalkylmercaptophenoxy derivatives;
- 4-oligoalkylaminophenyl or 4-oligoalkylaminophenoxy derivatives;
- (4-oligoalkylbenzyl)phenyl or (4-oligoalkylbenzyl)phenoxy derivatives;
- (4-oligoalkoxybenzyl)phenyl or (4-oligoalkoxybenzyl)phenoxy derivatives;
- trityl derivatives;
- benzyloxyaryl or benzyloxyalkyl derivatives;
- xanthene-3-yloxyalkyl derivatives;
- (4-alkylphenyl) or o-(4-alkylphenoxy)alkanoic acid derivatives;
- oligoalkylphenoxyalkyl or oligoalkoxyphenoxyalkyl derivatives;
- carbamate derivatives;
- amines;
- trialkylsilyl or dialkylalkoxysilyl derivatives;
- alkyl or aryl derivatives; and
- combinations thereof,

29 (currently amended): The ~~peptide~~ compound according to claim 25, characterized by being bound to a solid phase.

- 30 (currently amended): The ~~peptide~~ compound according to claim 25, characterized by being bound to a solid phase through a spacer.
- 31 (currently amended): A medicament for treatment of dilatative cardiomyopathy containing the ~~peptide~~ compound according to claim 25 in combination with a carrier.
- 32 (previously presented): A method of treating dilatative cardiomyopathy comprising administering to a patient the medicament according to claim 31.
- 33 (currently amended): A method of dilatative cardiomyopathy therapy comprising removing  $\beta_1$ -adrenergically active auto-antibodies from a patient's blood by extracorporeal treatment with the ~~peptide~~ compound according to claim 28 bound to a solid phase.
- 34 (currently amended): A device for chromatography comprising the ~~peptide~~ compound according to claim 28 bound to a solid phase.